Pangalis G A, Trangas T, Papanastasiou C J, Roussou P A, Tsiapalis C M
Acta Haematol. 1985;74(1):31-4. doi: 10.1159/000206160.
Poly(A)-polymerase enzymic activity was biochemically determined in lymphocytic extracts from 40 patients with chronic lymphocytic leukemia of the B cell type. The enzymic activities of patients with stage A, B and C disease were (U/mg of protein): 4.9 +/- 5.5, 12.5 +/- 7.5 and 20.9 +/- 18.9, respectively. The difference in the enzyme level between stage A and C patients was statistically significant (p less than 0.05). Comparison of the enzyme activity level in relation to the pattern of bone marrow involvement revealed that patients with a diffuse pattern of infiltration had a significantly higher enzyme level (17.9 +/- 15.5 U/mg of protein) than patients with interstitial or mixed infiltration patterns (5.9 +/- 6.6 and 7.9 +/- 7.0 U/mg of protein; p less than 0.025). Finally, patients who required treatment for their disease also had a significantly higher poly(A)-polymerase activity level (14.5 +/- 13.9 U/mg of protein) than patients with stable disease (4.9 +/- 5.5 U/mg of protein; p less than 0.05). Our results indicate that the enzyme poly(A)-polymerase may be used as a biological marker in patients with chronic lymphocytic leukemia.
对40例B细胞型慢性淋巴细胞白血病患者的淋巴细胞提取物进行了聚腺苷酸聚合酶酶活性的生化测定。A期、B期和C期疾病患者的酶活性(单位/毫克蛋白质)分别为:4.9±5.5、12.5±7.5和20.9±18.9。A期和C期患者之间的酶水平差异具有统计学意义(p<0.05)。根据骨髓受累模式比较酶活性水平发现,弥漫性浸润模式的患者酶水平(17.9±15.5单位/毫克蛋白质)显著高于间质或混合浸润模式的患者(5.9±6.6和7.9±7.0单位/毫克蛋白质;p<0.025)。最后,需要对疾病进行治疗的患者聚腺苷酸聚合酶活性水平(14.5±13.9单位/毫克蛋白质)也显著高于病情稳定的患者(4.9±5.5单位/毫克蛋白质;p<0.05)。我们的结果表明,聚腺苷酸聚合酶可作为慢性淋巴细胞白血病患者的一种生物学标志物。